Published in

American Society of Hematology, Blood Advances, 9(3), p. 1546-1552, 2019

DOI: 10.1182/bloodadvances.2019000123

Links

Tools

Export citation

Search in Google Scholar

Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Key Points FDG-PET–negative status achieved with salvage therapy is the most important determinant of favorable outcome after HSCT, for patients with R/R cHL. Our modified Bv+Bs salvage regimen led to deep metabolic responses in the majority of patients, establishing a bridge to transplant.